These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25551385)

  • 1. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
    Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ
    PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury.
    McBride JM; Smith DT; Byrn SR; Borgens RB; Shi R
    Neuroscience; 2007 Aug; 148(1):44-52. PubMed ID: 17629412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
    Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R
    Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 4-aminopyridine derivatives in dogs.
    Olby NJ; Smith DT; Humphrey J; Spinapolice K; Parke N; Mehta PM; Dise D; Papich M
    J Vet Pharmacol Ther; 2009 Oct; 32(5):485-91. PubMed ID: 19754916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High doses of 4-aminopyridine improve functionality in chronic complete spinal cord injury patients with MRI evidence of cord continuity.
    Grijalva I; García-Pérez A; Díaz J; Aguilar S; Mino D; Santiago-Rodríguez E; Guizar-Sahagún G; Castañeda-Hernández G; Maldonado-Julián H; Madrazo I
    Arch Med Res; 2010 Oct; 41(7):567-75. PubMed ID: 21167397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma.
    McBride JM; Smith DT; Byrn SR; Borgens RB; Shi R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):237-42. PubMed ID: 16297607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric emptying effect by 4-aminopyridine in patients with chronic spinal cord injury.
    Grijalva I; Guízar-Sahagún G; Rodríguez-Pacheco D; Francisco-Argüelles C; Castañeda-Hernández G; Palma-Aguirre JA
    Arch Med Res; 2007 May; 38(4):392-7. PubMed ID: 17416285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
    Hansebout RR; Blight AR; Fawcett S; Reddy K
    J Neurotrauma; 1993; 10(1):1-18. PubMed ID: 8320728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial.
    Blight AR; Toombs JP; Bauer MS; Widmer WR
    J Neurotrauma; 1991; 8(2):103-19. PubMed ID: 1870134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.
    Wolfe DL; Hayes KC; Hsieh JT; Potter PJ
    J Neurotrauma; 2001 Aug; 18(8):757-71. PubMed ID: 11526982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
    Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
    Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
    Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial.
    DeForge D; Nymark J; Lemaire E; Gardner S; Hunt M; Martel L; Curran D; Barbeau H
    Spinal Cord; 2004 Dec; 42(12):674-85. PubMed ID: 15356676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gait scoring in dogs with thoracolumbar spinal cord injuries when walking on a treadmill.
    Olby NJ; Lim JH; Babb K; Bach K; Domaracki C; Williams K; Griffith E; Harris T; Muguet-Chanoit A
    BMC Vet Res; 2014 Mar; 10():58. PubMed ID: 24597771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease.
    Smith DT; Shi R; Borgens RB; McBride JM; Jackson K; Byrn SR
    Eur J Med Chem; 2005 Sep; 40(9):908-17. PubMed ID: 16055230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured guinea pig spinal cord white matter.
    Sun W; Smith D; Fu Y; Cheng JX; Bryn S; Borgens R; Shi R
    J Neurophysiol; 2010 Jan; 103(1):469-78. PubMed ID: 19923250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.